Scientific paper - Original scientific paper
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
Diabetology, 5 (2024), 1; 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina; Belančić, Andrej; Jug, Juraj; Mustač, Filip; Sirovica, Maja; Santini, Mihovil; Bošnjaković, Anja; Lovrić, Mario; Lovrić Benčić, Martina

Cite this document

Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M. ... Lovrić Benčić, M. (2024). Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology, 5. (1), 26-39. doi: 10.3390/diabetology5010003

Matovinović, Martina, et al. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology, vol. 5, no. 1, 2024, pp. 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić and Martina Lovrić Benčić. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology 5, no. 1 (2024): 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, M., et al. (2024) 'Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?', Diabetology, 5(1), pp. 26-39. doi: 10.3390/diabetology5010003

Matovinović M, Belančić A, Jug J, Mustač F, Sirovica M, Santini M, and sur.. Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology [Internet]. 2024 January 04 [cited 2024 June 16];5(1):26-39. doi: 10.3390/diabetology5010003

M. Matovinović, et al., "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?", Diabetology, vol. 5, no. 1, pp. 26-39, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:769094. [Accessed: 16 June 2024]